Atlas Trials

Anrotinib and Tirelizumab in First-line Treatment of RM-NPC

Clinical trial NCT05981157 · UNKNOWN

Trial details

NCT number
NCT05981157
Sponsor
Zhongshan People's Hospital, Guangdong, China
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Nasopharyngeal Carcinoma
Start date
2023-06-01
Primary completion
2025-12-30
Enrollment
27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.